Trial reportPediatric nephrology (Berlin, Germany)2004
Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.
Trial report in Pediatric nephrology (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Trial
- Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2014Trial
- Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2013Trial
- Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.British journal of clinical pharmacology · 2010Trial
- Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2005Trial
- Article
- Mycophenolate mofetil for sustained remission in nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2018Article
- Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016Observational
- American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.European journal of pediatrics · 2013Article
- Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil.Pediatric nephrology (Berlin, Germany) · 2013Article
- Should we consider MMF therapy after rituximab for nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 2011Article
- New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Review
- An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.Nature clinical practice. Nephrology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term treatment with cyclosporin A (CyA) of children with frequently relapsing steroid-sensitive nephrotic syndrome (SSNS) carries the risk of nephrotoxicity. We have analyzed renal function in 23 children with SSNS during CyA therapy. Repeated measurements of glomerular filtration rate (single-shot 51Cr-EDTA clearance) showed a decline from 131 +/- 21 ml/min per 1.73 m2 to 116 +/- 27 ml/min per 1.73 m2 at last follow-up. Similarly, effective renal plasma flow (simultaneous 123 I-hippurate clearance) was correlated with duration of CyA treatment, and showed a decline from 980 +/- 318 ml/min per 1.73 m2 to 724 +/- 242 ml/min per 1.73 m2. In a pilot study we investigated the effect of mycophenolate mofetil (MMF) in 7 children with a median age of 12.7 years [6 with minimal change nephrotic syndrome (MCNS), 1 with focal segmental glomerulosclerosis (FSGS)] with signs of nephrotoxicity because of long-term CyA therapy. Only 1 patient with SSNS showed a relapse during MMF therapy. In the patient with FSGS, MMF was started in addition to CyA, resulting in complete remission for a follow-up of 28 months. This preliminary study demonstrates that children with MCNS treated with CyA may be successfully converted to MMF without major side effects. In all cases, including FSGS, MMF had a beneficial effect on renal function. These data should be confirmed by a prospective randomized clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.